Everything below concerns NAD+ salvage. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Common laboratory methods for NMN include high-performance liquid chromatography with ultraviolet detection, liquid chromatography coupled to mass spectrometry, and nuclear magnetic resonance spectroscopy. Because the nicotinamide ring absorbs ultraviolet light, HPLC-UV at wavelengths near 260 nm can be used for purity assessment. LC-MS and LC-MS/MS provide greater sensitivity and are often applied to biological samples. Identification typically relies on matching retention time, mass-to-charge ratio, and fragmentation pattern to a reference standard.
NMN is generally handled as a hygroscopic and light-sensitive solid in laboratory settings. Recommended storage is typically at -20°C or below, often under desiccation and protected from light. Aqueous solutions are less stable than the solid and may degrade through hydrolysis or other pathways, so fresh preparation is common for analytical work. Repeated freeze-thaw cycles can reduce sample integrity. Stability depends on pH, temperature, buffer composition, and the presence of metal ions, so specific shelf-life values should be determined experimentally rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide mononucleotide | Often abbreviated NMN |
| Chemical formula | C11H15N2O8P | Beta anomer form |
| Molecular mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | Beta-NMN |
| Appearance | White to off-white powder | Typical laboratory grade |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Regulatory treatment varies by country. In the United States, NMN has been marketed as a dietary supplement, but the Food and Drug Administration has stated that it is excluded from the dietary supplement definition because it was authorized for investigation as a new drug before being marketed as a supplement. Other jurisdictions may treat it as a novel food, a supplement, or an unapproved drug ingredient. Import and sale rules can therefore differ substantially.
Quality control for NMN focuses on identity, purity, residual solvents, heavy metals, and microbial limits. Because the molecule can absorb water, moisture content and packaging are relevant to shelf life. Suppliers may provide certificates of analysis, but independent verification is often needed for research or commercial use. The long-term stability of different crystal forms, salt forms, and formulations is not fully characterized in the public literature. Some degradation products and their effects on product performance remain open questions.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Laboratory testing in the United States is subject to federal regulation. Clinical laboratories performing testing are overseen by the Centers for Medicare and Medicaid Services (CMS) utilizing national standards established under the Clinical Laboratory Improvement Amendments (CLIA). The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) assist CMS in this process. CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
Microbial toxins are toxins produced by micro-organisms, including bacteria, fungi, protozoa, dinoflagellates, and viruses. Many microbial toxins promote infection and disease by directly damaging host tissues and by disabling the immune system. Endotoxins most commonly refer to the lipopolysaccharide (LPS) or lipooligosaccharide (LOS) that are in the outer plasma membrane of Gram-negative bacteria. The botulinum toxin, which is primarily produced by Clostridium botulinum and less frequently by other Clostridium species, is the most toxic substance known in the world. However, microbial toxins also have important uses in medical science and research. Currently, new methods of detecting bacterial toxins are being developed to better isolate and understand these toxins. Potential applications of toxin research include combating microbial virulence, the development of novel anticancer drugs and other medicines, and the use of toxins as tools in neurobiology and cellular biology.
Research into virtual reality (VR) hardware and software started as early as 1968 by Ivan Sutherland and his student Bob Sproull, but most equipment was too expensive for consumer use, and its use for games was limited. The first VR head mounted display was connected to a computer. In the late 1980s, Jaron Lanier and Thomas G. Zimmerman, former programmers for Atari, Inc., began developing hardware under the name VPL Research, with Lanier coining the term "virtual reality" for their products. One of VPL's products was the VPL DataGlove; a glove that sensed the user's finger movement and translated it into computer input. The idea inspired engineers at Abrams/Gentile Entertainment (AGE) to work with Mattel and Nintendo to build a low-cost version of the DataGlove to work with the Nintendo Entertainment System (NES), omitting much of the technical sophistication and movement sensitivity of the DataGlove as to achieve a reasonable consumer cost. The Power Glove was released in 1989. The games Super Glove Ball and Bad Street Brawler were specifically designed to use the Power Glove, while other NES games could be played using the Power Glove by mapping its output to various controls. About one million Power Glove units were sold before Mattel discontinued it in 1990. Its low cost compared to the DataGlove and other similar gloves led academics to buy the unit for their own research.
Sources: en.wikipedia.org
==== Binary compounds ==== Potassium forms many binary compounds, i.e., compounds of potassium and one other element. The inventory is so extensive that one gap merits mention: no nitride of potassium is known. Potassium hydride forms directly from the elements:
== Insulin pen == Reith's daughter was diagnosed with Type 1 diabetes when she was four. When her daughter was five, they travelled from Glasgow to London by train as the family relocated to Scotland, and Reith had to use the public toilets at Euston Station to inject her with insulin, a process involving drawing the insulin from a glass phial using a steel hypodermic syringe, which would later require being boiled to re-sterilise it. The inconvenience, discomfort and hygiene implications of this situation led her to conceive a reusable, cartridge-based system. She developed the idea at the Southern General Hospital from 1978 with her colleague and fellow physician John Ireland, and John Paton, a bioengineer recruited at the University of Glasgow's Department of Clinical Physics and Bio-Engineering, for the project. The invention was announced in a January 1981 paper in The Lancet by Reith alongside Ireland, Paton and Margaret Wilson, also of Southern General. It described the use of the prototype, based on a device known as the Becton-Dickinson 'Plastipak' self-contained insulin syringe, by seven patients aged from 8 to 49. Further clinical trials commenced the same year, using 100 pens and 5,000 insulin cartridges funded by Diabetes UK. Within two years the world's first insulin pen, branded "Penject", entered general use.
== Distribution and habitat == The death cap is native to Europe, where it is widespread. It is found from the southern coastal regions of Scandinavia in the north, to Ireland in the west, east to Poland and western Russia, and south throughout the Balkans, in Greece, Italy, Spain, and Portugal in the Mediterranean basin, and in Morocco and Algeria in north Africa. In west Asia, it has been reported from forests of northern Iran. There are records from further east in Asia but these have yet to be confirmed as A. phalloides. By the end of the 19th century, Charles Horton Peck had reported A. phalloides in North America. In 1918, samples from the eastern United States were identified as being a distinct though similar species, A. brunnescens, by George Francis Atkinson of Cornell University. By the 1970s, it had become clear that A. phalloides does occur in the United States, apparently having been introduced from Europe alongside chestnuts, with populations on the West and East Coasts. A 2006 historical review concluded the East Coast populations were inadvertently introduced, likely on the roots of other purposely imported plants such as chestnuts. The origins of the West Coast populations remained unclear, due to scant historical records, but a 2009 genetic study provided strong evidence for the introduced status of the fungus on the west coast of North America. Observations of various collections of A. phalloides, from conifers rather than native forests, have led to the hypothesis that the species was introduced to North America multiple times.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.
No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.
Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.
NMN is commonly detected by HPLC-UV, LC-MS, or LC-MS/MS. These methods separate the compound from related substances and identify it by retention time and mass.